A NOVEL RNA INTERFERENCE THERAPY TO REDUCE CARDIOVASCULAR RISK BY LOWERING LIPOPROTEIN(A) LEVELS USING THE LEPODISIRAN AGENT. (2026). Journal of Multidisciplinary Sciences and Innovations, 5(03), 1550-1553. https://doi.org/10.55640/